MA28035A1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA28035A1
MA28035A1 MA28868A MA28868A MA28035A1 MA 28035 A1 MA28035 A1 MA 28035A1 MA 28868 A MA28868 A MA 28868A MA 28868 A MA28868 A MA 28868A MA 28035 A1 MA28035 A1 MA 28035A1
Authority
MA
Morocco
Prior art keywords
rotavirus
vaccine
serotype
inducing
patient
Prior art date
Application number
MA28868A
Other languages
English (en)
Inventor
Desiree Alberte Colau Brigitte
Arsene Virginie De Vos Beatrice
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0414787.2A external-priority patent/GB0414787D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA28035A1 publication Critical patent/MA28035A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé qui permet d'induire une réponse immunitaire contre une infection par un rotavirus provenant d'un sérotype du rotavirus. Ledit procédé consiste à administrer au patient une composition renfermant un vaccin de rotavirus atténué d'un sérotype différent.
MA28868A 2003-09-02 2006-03-10 Vaccin MA28035A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49943003P 2003-09-02 2003-09-02
GBGB0414787.2A GB0414787D0 (en) 2004-07-01 2004-07-01 Method

Publications (1)

Publication Number Publication Date
MA28035A1 true MA28035A1 (fr) 2006-07-03

Family

ID=34276843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28868A MA28035A1 (fr) 2003-09-02 2006-03-10 Vaccin

Country Status (17)

Country Link
EP (2) EP2272532B1 (fr)
JP (1) JP5588586B2 (fr)
KR (1) KR20060126917A (fr)
AU (1) AU2004268375B2 (fr)
BR (1) BRPI0414073A (fr)
CA (1) CA2536734C (fr)
HR (2) HRP20130407T1 (fr)
IL (1) IL173921A0 (fr)
IS (1) IS2922B (fr)
MA (1) MA28035A1 (fr)
MX (1) MXPA06002459A (fr)
NO (1) NO342397B1 (fr)
NZ (1) NZ545639A (fr)
PL (2) PL2272532T3 (fr)
RU (1) RU2368392C2 (fr)
SG (1) SG147465A1 (fr)
WO (1) WO2005021033A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1915173A2 (fr) * 2005-08-17 2008-04-30 GlaxoSmithKline Biologicals S.A. Vaccin anti-rotavirus inducteur de protection croisee heterotipique
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
CA2797059A1 (fr) * 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Nouveau procede
US9044498B2 (en) * 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
CA2819246C (fr) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Formulations de virus liquides
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
IL269184B2 (en) * 2018-05-07 2025-08-01 Univ North Carolina Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
ATE170081T1 (de) * 1990-11-16 1998-09-15 Childrens Hosp Medical Center Humane rotativen, impfstoffe und methoden
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
WO1998056415A1 (fr) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Saponines purifiees servant d'adjuvants oraux
AU767885B2 (en) * 1999-08-17 2003-11-27 Smithkline Beecham Biologicals (Sa) Vaccine

Also Published As

Publication number Publication date
IS8325A (is) 2006-02-23
EP1660123B1 (fr) 2013-03-13
NO20060976L (no) 2006-03-31
PL1660123T3 (pl) 2013-08-30
EP2272532A3 (fr) 2012-08-01
MXPA06002459A (es) 2006-06-20
WO2005021033A2 (fr) 2005-03-10
NO342397B1 (no) 2018-05-14
PL2272532T3 (pl) 2016-07-29
JP5588586B2 (ja) 2014-09-10
WO2005021033A3 (fr) 2005-05-06
BRPI0414073A (pt) 2006-10-24
NZ545639A (en) 2009-04-30
HRP20160299T1 (hr) 2016-04-22
RU2368392C2 (ru) 2009-09-27
RU2006106427A (ru) 2007-10-10
CA2536734A1 (fr) 2005-03-10
AU2004268375B2 (en) 2010-01-28
HRP20130407T1 (en) 2013-06-30
AU2004268375A1 (en) 2005-03-10
EP2272532B1 (fr) 2016-02-10
EP2272532A2 (fr) 2011-01-12
IL173921A0 (en) 2006-07-05
JP2007516215A (ja) 2007-06-21
SG147465A1 (en) 2008-11-28
KR20060126917A (ko) 2006-12-11
EP1660123A2 (fr) 2006-05-31
IS2922B (is) 2015-04-15
CA2536734C (fr) 2014-07-08

Similar Documents

Publication Publication Date Title
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
MA30866B1 (fr) Vaccin
ATE419872T1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
WO2005097211A3 (fr) Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation
NO20010922D0 (no) FremgangsmÕte for DNA vaksinering
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
ATE426412T1 (de) Adjuvante influenza-vakzine
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
TR200103574T2 (tr) Amid ikameli/katkılı imidazokinolinler
LU92262I2 (fr) Vaccin méningococcique groupe B (ADNr, composant, adsorbé) et ses dérivés pharmaceutiquement acceptables (BEXSERO)
HRP20041152B1 (hr) Farmaceutske formulacije
NO20076239L (no) Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom
MY129263A (en) Vaccine composition
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
MA29601B1 (fr) Vaccin antipaludeen
BRPI0510430A (pt) composições e métodos para vacinação mucosal
EP1385541A4 (fr) Compositions immunostimulantes comprenant un phosphate d'aminoalkyl glucosaminide et du qs-21
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
MA28035A1 (fr) Vaccin
MA32030B1 (fr) Vaccins anti-malaria
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
EP1565583A4 (fr) Formulations de vaccin anti-vih
MA29133B1 (fr) Nouvelle combinaison
DE60115051D1 (de) Immunologische adjuvans verbindungen